Ex Vivo Drug Sensitivity Testing and Mutation Profiling
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 16
Summary
- Conditions
- Recurrent Childhood Ependymoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Brain Tumor
- Recurrent Childhood Brainstem Glioma
- Recurrent Childhood Gliosarcoma
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Childhood Malignant Germ Cell Neoplasm
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Rhabdomyosarcoma
- Refractory Childhood Hodgkin Lymphoma
- Recurrent Childhood Soft Tissue Sarcoma
- Refractory Childhood Acute Lymphoblastic Leukemia
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Younger than 21 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVE: The primary objective of the study is to determine feasibility of providing pediatric cancer patients with access to personalized treatment options and clinical management recommendations based on ex vivo drug sensitivity testing (DST) and genomic profiling. SECONDARY OBJECTIVE: T...
PRIMARY OBJECTIVE: The primary objective of the study is to determine feasibility of providing pediatric cancer patients with access to personalized treatment options and clinical management recommendations based on ex vivo drug sensitivity testing (DST) and genomic profiling. SECONDARY OBJECTIVE: The secondary objective of the study is to compare individual outcomes (response and disease-free survival) in patients with pediatric cancers treated with DST-guided therapy as compared to non-DST guided (conventional) therapy. EXPLORATORY OBJECTIVE: To explore associations between genetic abnormalities in malignancies and ex vivo drug response.
Tracking Information
- NCT #
- NCT03860376
- Collaborators
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
- Investigators
- Principal Investigator: Diana Azzam, PhD Florida International University Principal Investigator: Daria Salyakina, PhD Nicklaus Children's Hospital